Opinion|Videos|October 30, 2023

Future Perspectives in the Treatment and Management of Patients With EGFR-Mutated NSCLC

Author(s)Misako Nagasaka, MD, PhD, Kristen Neumann, DNP, FNP-C

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C, emphasize the importance of patient education, discussing how understanding the biological reasons behind treatments for EGFR-mutated non-small cell lung cancer and their side effects can lead to better outcomes, and highlighting the need for collaborative care and clear communication.

Episodes in this series

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C

EP. 1 Managing Treatment-Related Rashes in Patients With EGFR-Mutated NSCLC

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C

EP. 2 Managing Treatment-Related Diarrhea in Patients With EGFR-Mutated NSCLC

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C

EP. 3 Implementing Dose Reductions and Dose Holds in Patients With EGFR-Mutated NSCLC Receiving TKIs

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C

EP. 4 Multidisciplinary Management of Treatment-Related Adverse Events in Patients With EGFR-Mutated NSCLC

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C

EP. 5 Amivantamab for Patients With NSCLC and an EGFR Exon 20 Mutation

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C

EP. 6 Educating Patients and Clinical Staff on Infusion-Related Adverse Reactions Seen With Amivantamab in NSCLC With EGFR Exon 20 Mutations

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C

EP. 7 Future Perspectives in the Treatment and Management of Patients With EGFR-Mutated NSCLC

EP. 8 Approaches to Biomarker Testing in Non-Small Cell Lung Cancer (NSCLC)

EP. 8 Approaches to Biomarker Testing in Non-Small Cell Lung Cancer (NSCLC)

EP. 9 EGFR Mutations in Patients With NSCLC

EP. 9 EGFR Mutations in Patients With NSCLC

EP. 10 Adverse Effect Management in Non–Small Cell Lung Cancer Treatment

EP. 10 Adverse Effect Management in Non–Small Cell Lung Cancer Treatment

EP. 11 Patient Case Presentation: A 59-Year-Old Man With EGFR-Mutant NSCLC

EP. 11 Patient Case Presentation: A 59-Year-Old Man With EGFR-Mutant NSCLC

EP. 12 The Future of Treatment for EGFR TKI Resistance in EGFR-Mutant NSCLC

EP. 12 The Future of Treatment for EGFR TKI Resistance in EGFR-Mutant NSCLC

Next steps for research in lung cancer may include identifying how the gut microbiome impacts responses and adverse effects associated with treatment, says Misako Nagasaka, MD, PhD.

EP. 13 Multidisciplinary Care, Approval Updates, and Future Research in NSCLC

EP. 14 Treatment Approaches for Patients With EGFR-Mutant NSCLC

EP. 14 Treatment Approaches for Patients With EGFR-Mutant NSCLC

EP. 15 Common Adverse Events Seen With EGFR TKIs in EGFR-Mutant NSCLC

EP. 15 Common Adverse Events Seen With EGFR TKIs in EGFR-Mutant NSCLC

EP. 16 Approaches to Managing Patients With EGFR-Mutant NSCLC and EGFR TKI Resistance

EP. 16 Approaches to Managing Patients With EGFR-Mutant NSCLC and EGFR TKI Resistance

EP. 17 Patient Case Presentation: A 69-Year-Old Man With NSCLC With EGFR Exon 20 Insertion Mutations

EP. 17 Patient Case Presentation: A 69-Year-Old Man With NSCLC With EGFR Exon 20 Insertion Mutations

EP. 18 Management Strategies for Adverse Events Seen With Amivantamab in NSCLC With EGFR Exon 20 Insertion Mutations

EP. 18 Management Strategies for Adverse Events Seen With Amivantamab in NSCLC With EGFR Exon 20 Insertion Mutations

EP. 19 The Future of Treatment for NSCLC With EGFR Exon 20 Insertion Mutations

EP. 19 The Future of Treatment for NSCLC With EGFR Exon 20 Insertion Mutations

EP. 20 Unmet Needs and Future Perspectives in NSCLC Treatment

EP. 20 Unmet Needs and Future Perspectives in NSCLC Treatment

EP. 21 New Lung Cancer Treatment Options Combine Neoadjuvant and Adjuvant Therapies

EP. 21 New Lung Cancer Treatment Options Combine Neoadjuvant and Adjuvant Therapies

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

Chinmay Jani, MD, describes how he counsels patients with and without a smoking history on a lung cancer diagnosis.

November 7th, 2026

Changing Mindsets and Removing Guilt Surrounding Lung Cancer Diagnoses

Chinmay Jani, MD, describes how he counsels patients with and without a smoking history on a lung cancer diagnosis.

Chinmay Jani, MD, discusses ASCO 2026 data on lung cancer trends in younger adults and why this group has been overlooked.

November 6th, 2026

Young Adults With Lung Cancer Often Fall Outside Screening Guidelines

Chinmay Jani, MD, discusses ASCO 2026 data on lung cancer trends in younger adults and why this group has been overlooked.

Chinmay Jani, MD, explains how air pollution and asbestos contribute to lung cancer deaths beyond tobacco.

November 5th, 2026

Air Pollution Emerges as Second Leading Risk Factor for Lung Cancer Deaths

Chinmay Jani, MD, explains how air pollution and asbestos contribute to lung cancer deaths beyond tobacco.

Surgery Correlates With Better Survival Vs SABR in Early-Stage NSCLC

November 3rd, 2026

Surgery Correlates With Better Survival Vs SABR in Early-Stage NSCLC

Findings may provide reassurance to patients with early-stage disease that surgery may help improve survival rates.

Chinmay Jani, MD, highlights non-smoking risk factors, the impact of lung cancer on younger populations, and the value of comprehensive molecular testing.

November 2nd, 2026

How Do Risk Factors and Genomic Advances Impact Lung Cancer Detection?

Chinmay Jani, MD, highlights non-smoking risk factors, the impact of lung cancer on younger populations, and the value of comprehensive molecular testing.

Dwight H. Owen, MBBCh, MS, discussed why severe immune-related toxicities remain hard to predict as immunotherapy combinations expand in lung cancer.

October 30th, 2026

Predicting Severe Immune-Related Toxicities in Lung Cancer Immunotherapy

Dwight H. Owen, MBBCh, MS, discussed why severe immune-related toxicities remain hard to predict as immunotherapy combinations expand in lung cancer.

Mingjia Li, MD, discussed the limitations of current biomarkers in selecting patients with resectable NSCLC for neoadjuvant chemoimmunotherapy.

October 30th, 2026

Better Biomarkers Needed to Guide Neoadjuvant Chemoimmunotherapy in NSCLC

Mingjia Li, MD, discussed the limitations of current biomarkers in selecting patients with resectable NSCLC for neoadjuvant chemoimmunotherapy.

Key Multidisciplinary Takeaways for Lung Cancer Care From ESMO 2026

October 30th, 2026

Key Multidisciplinary Takeaways for Lung Cancer Care From ESMO 2026

Presentations at ESMO Congress 2026 detailed how surgery, radiation oncology, and supportive care can contribute to the treatment of patients with NSCLC.

Trending on CancerNetwork

What Separates a Next-Generation Liver Tumor Board From the Traditional Model?

Weighing Immunotherapy for Bridging and Downstaging Before HCC Transplant

BOT+BAL Yields Long-Term Survival in Patients With Refractory MSS mCRC

MASLD Raises Liver and Other Cancer Risks, Supporting Selective HCC Surveillance

Tambiciclib Combo Shows Activity in Relapsed/Refractory Post-Venetoclax AML